The Healthy and At-Risk Populations program (HARP) has 34 core members representing four schools and 13 departments in total. During the current funding year, cancer-related funding for this program totaled $20.8M in total costs. Of this amount, peer-reviewed funding totaled $13.5M in total costs, including $3.4M from the National Cancer Institute. As with other programs, JCCC fosters a number of interactive activities and shared resources that support investigators in HARP. During the current grant cycle, funds from the JCCC in the form of the CCSG Developmental Funds, institutional support and philanthropic gifts to HARP total $2,043,085. These funds supported seed grants, program area leadership support, as well as the annual disparities symposium hosted by HARP in the community. The HARP program is highly interactive, with 15% of its publications reflecting intra-programmatic efforts and 11 % reporting inter-programmatic collaborations. 178 (28%) appeared in high-impact journals. Accruals to prevention trials totaled 1,186, screening 1,021, early detection/diagnostic 1,151, epidemiologic/obs/outcome 1,426, correlative 113. The goals of the HARP are to advance understanding of cancer risk and protective factors and to identify strategies to make the latest cancer prevention knowledge and technologies accessible to the population at large. HARP research spans four broad focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects supporting community engagement. Two major themes characterize the research of this program: cancer disparities and translational research (mainly T3 and T4). These themes are not mutually exclusive, and in fact most projects in the program incorporate both. Our cancer disparities research focuses on cancer prevention and control interventions to mitigate disparities in low-income, ethnic minority and other socially and medically underserved populations in Los Angeles and beyond and has brought recognition to UCLA as one of the premier cancer disparities research programs in the nation.
The Healthy and At-Risk Populations Program (HARP) has 34 core members conducting work within four focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects to support community engagement. Two major themes, which cut across the four focus areas, characterize the research in HARP: cancer disparities and translational research.
|Law, Ivy Ka Man; Jensen, Dane; Bunnett, Nigel W et al. (2016) Neurotensin-induced miR-133Î± expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep 6:22195|
|Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40|
|Palanichamy, Jayanth Kumar; Tran, Tiffany M; Howard, Jonathan M et al. (2016) RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest 126:1495-511|
|Van Dyk, Kathleen; Ganz, Patricia A; Ercoli, Linda et al. (2016) Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer 24:4939-4949|
|Bostean, Georgiana; Crespi, Catherine M; Vorapharuek, Patsornkarn et al. (2016) E-cigarette use among students and e-cigarette specialty retailer presence near schools. Health Place 42:129-136|
|Aguilera-Sandoval, Christian R; Yang, Otto O; Jojic, Nebojsa et al. (2016) Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS 30:701-11|
|Bauer, Margaret R; Harris, Lauren N; Wiley, Joshua F et al. (2016) Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis. Ann Behav Med 50:370-84|
|Horvath, Steve; Gurven, Michael; Levine, Morgan E et al. (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol 17:171|
|Ganz, Patricia A; Petersen, Laura; Bower, Julienne E et al. (2016) Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 34:816-24|
|Dooley, Larissa N; Ganz, Patricia A; Cole, Steve W et al. (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord 197:43-50|
Showing the most recent 10 out of 568 publications